Achieve Life Sciences

ACHVNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$835.568 M

$8.12 +0.87%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$54.6M

Loss-making

Shares outstanding

102,902,490

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#5Celldex TherapeuticsCLDX$2.63B
#6Intellia TherapeuticsNTLA$1.78B
#7Achieve Life SciencesACHV$835.6M
#8Anbio BiotechnologyNNNN$802.9M
#9QuidelOrthoQDEL$750.2M

What if Achieve Life Sciences were worth as much as…

Open the what-if tool →

Gold $30.2T

$293,811.84

Per share 36,184× higher

Bitcoin $1.74T

$16,925.30

Per share 2,084× higher

Nvidia $5.52T

$53,601.88

Per share 6,601× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Achieve Life Sciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.